Advertisement
Advertisement
ATRA
Atara Biotherapeutics, Inc
8.81
USDSponsored
+0.27
+3.16%
Sep 25, 15:59 UTC -4
Closed
After-Market
8.81
0.00
+0.06%
ATRA Earnings Reports
Positive Surprise Ratio
ATRA beat 21 of 43 last estimates.
49%
Next Report
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$680.00K
/-$0.14
Implied change from Q2 26 (Revenue/ EPS)
+7.94%
/-56.25%
Implied change from Q3 25 (Revenue/ EPS)
-80.31%
/-56.25%
Atara Biotherapeutics, Inc earnings per share and revenue
On Aug 12, 2026, ATRA reported earnings of -0.32 USD per share (EPS) for Q2 26, beating the estimate of -0.32 USD, resulting in a 0.40% surprise. Revenue reached 630.00 thousand, compared to an expected 374.00 thousand, with a 68.45% difference. The market reacted with a -7.75% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.14 USD, with revenue projected to reach 680.00 thousand USD, implying an decrease of -56.25% EPS, and increase of 7.94% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Atara Biotherapeutics, Inc's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Atara Biotherapeutics, Inc reported EPS of -$0.32, missing estimates by 0.4%, and revenue of $630.00K, 68.45% above expectations.
How did the market react to Atara Biotherapeutics, Inc's Q2 2026 earnings?
The stock price moved down -7.75%, changed from $9.22 before the earnings release to $8.51 the day after.
When is Atara Biotherapeutics, Inc expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Atara Biotherapeutics, Inc's next earnings report?
Based on 4
analysts, Atara Biotherapeutics, Inc is expected to report EPS of -$0.14 and revenue of $680.00K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.